&w=3840&q=100)
Bharat Biotech, GSK partner to develop vaccine for Shigella diarrhoea
As part of this agreement, Bharat Biotech will lead the further development of altSonflex1-2-3, including Phase 3 clinical trials, regulatory advancement, and large-scale manufacturing
Press Trust of India New Delhi
Bharat Biotech on Thursday said it has partnered with GSK plc for the development of a vaccine for Shigellosis, a severe form of bacterial diarrhoea.
The altSonflex1-2-3 vaccine candidate, developed by GSK and now advancing through a strategic collaboration with Bharat Biotech, represents one of the most advanced Shigella vaccine candidates globally, the company said in a statement.
With no licensed Shigella vaccine currently available and rising antimicrobial resistance, this candidate stands out for its broad serotype coverage, innovative Generalized Modules for Membrane Antigens (GMMA)-based platform, and robust early clinical results, it added.
"With no approved vaccine currently available and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries," Bharat Biotech Executive Chairman Krishna Ella said.
As part of this agreement, Bharat Biotech will lead the further development of altSonflex1-2-3, including Phase 3 clinical trials, regulatory advancement, and large-scale manufacturing.
GSK will continue to support the programme by assisting with clinical trial design, securing external funding, and contributing to the Access and Delivery Plans and commercialisation strategy.
"This agreement allows us to combine our strengths in science, research, and technology with Bharat Biotech's capacity to develop and deliver vaccines at scale, potentially preventing illness and saving lives around the world," GSK Chief Global Health Officer Thomas Breuer said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Print
an hour ago
- The Print
India will soon have its own satellites to monitor spy satellites. How the technology works
'India will be focusing on improving its presence in space in the coming years. This initiative will be a part of that larger aim,' a senior ISRO official said. The project being undertaken by the Defence Ministry, which is in the process of being finalised, will have 'satellite mapping' capabilities and will be fully made in India, senior officials from the Indian Space Research Organisation (ISRO) told ThePrint. New Delhi: Spy satellites to monitor other spy satellites. India will soon have its own constellation of satellites to keep an eye out for other satellites that might be surveilling India. This network of satellites will enhance India's space domain awareness and will also help monitor orbital threats in real-time. The project is being overseen under NETRA, a Network for Tracking Space Objects and Analysis, which detects space debris and other hazardous space objects. The official said that while ISRO will partner with the MoD in overseeing the overall design and monitoring of these satellites, a private Bengaluru-based space start-up, Digantara, has been contracted to deploy these satellites within the next year. How does satellite mapping work? The capabilities of monitoring foreign satellites is being acquired by countries including the US, Russia and China. These satellites have propulsion and guidance systems that utilise factors such as orbital inclinations and altitudes to get information and photographs from a potential target satellite. Some of these satellites are also capable of intercepting inter-satellite communications and links to ground stations. Varying versions of such technology are either already deployed or are currently being tested. In 2020, the US Space Command—an agency responsible for tracking all objects in orbit—flagged that the Russian satellite Kosmos 2543 had released an unknown object into space. This was believed to be a test of a new technology that could be used to destroy objects already in orbit. The Russian satellite released this tech in close proximity to another Russian satellite. 'Space is increasingly becoming a weapon for countries. Battles will no longer be limited to just the ground, but will also be fought in space. And countries need to be ready for it,' the ISRO official said. Focus on active orbital security India is already working on increasing its defence capabilities in space. Its next 'spy satellite programme', space-based surveillance-3 or SBS-3, will launch a constellation of 52 surveillance satellites in the coming two years. Three private space startups, Ananth Technologies, Centum Electronics and Alpha Design Technologies, have joined hands with the government to give shape to this project. The Rs 27,000 crore project is set to significantly improve India's national security capabilities. (Edited by Viny Mishra) Also read: DRDO eyes persistent high-altitude surveillance edge as Stratospheric Airship soars in maiden trial
Hindustan Times
7 hours ago
- Hindustan Times
Health Talk: Bharat Biotech-GSK's Shigella vaccine candidate holds promise
Hyderabad-based Bharat Biotech has partnered with GSK—a British multinational pharmaceutical and biotechnology company—for the ongoing development and potential use of the Shigella vaccine candidate, altSonflex1-2-3, the companies announced in a joint statement on Thursday. The partnership will mark a critical step in the advancement of this promising vaccine, targeting Shigellosis—a severe form of bacterial diarrhoea that disproportionately affects children under five in low- and middle-income countries. India is also impacted. A 2021 study published in the Indian Journal of Medical Biology— Antimicrobial Resistant Shigella in North India Since the Turn of the 21st Century — talks about how the ubiquitous presence and rampant spread of Shigellosis in Asian and African countries, along with the emergence of antibiotic-resistant strains, is particularly concerning. 'The scientific community must focus efforts to identify the drugs most suitable for empirical therapy according to these antibiograms. To decrease the morbidity and mortality associated with diarrhea in our country, we not only need newer antimicrobials, cost-effective vaccines but also public health measures such as safe drinking water and sanitation…,' concluded researchers in the paper. Talking about the partnership, Bharat Biotech executive chairman Krishna Ella said, 'As the market leader in vaccines for diarrhoeal infections, including rotavirus, typhoid, polio, non-typhoidal salmonella, cholera, and paratyphi, Bharat Biotech is proud to partner with GSK to develop a next-generation Shigella vaccine candidate, for a severe form of bacterial diarrhoea affecting millions of children under five.' 'With no approved vaccine currently available and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low- and middle-income countries. This collaboration combines our strengths in innovation, manufacturing, and global health commitment. The use of Generalised Modules for Membrane Antigens (GMMA) technology reflects our mission to deliver accessible vaccines that protect and improve lives worldwide,' Ella added. According to the statement issued, altSonflex1-2-3 has already shown encouraging results in early-stage clinical trials. 'A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong immune response. Subsequent Phase 2 trials in Africa, including vaccination of 9-month-old infants—the primary target population—reported no safety concerns. Interim results from 2024 confirmed that the candidate met its pre-set immunogenicity goals,' it read. The vaccine candidate represents one of the most advanced Shigella vaccine candidates globally. With no licensed Shigella vaccine currently available and rising antimicrobial resistance, this candidate stands out for its broad serotype coverage, innovative GMMA-based platform, and robust early clinical results. GMMA technology is an innovative platform that uses bacterial outer membranes to deliver the O Antigen to the immune system. This approach allows for high-yield production with a simple and cost-effective manufacturing process, offering a pathway to create affordable vaccines for underserved populations. As part of this agreement, Bharat Biotech will lead the further development of the vaccine candidate, including Phase 3 clinical trials, regulatory advancement, and large-scale manufacturing. GSK will continue to support the programme by assisting with clinical trial design, securing external funding, and contributing to the access and delivery plans and commercialisation strategy. 'With young children in lower-income countries disproportionately impacted by Shigella, the development of a low-cost vaccine is an important goal for global public health. With no licensed vaccines widely available, the development of our Shigella vaccine candidate, which has demonstrated promising clinical trial results, fills us with immense pride,' GSK chief global health officer Thomas Breuer said. Having effective vaccines, which are also cost-effective, can reduce the overall disease burden significantly.
The Hindu
14 hours ago
- The Hindu
Resurgence of COVID 19 in India – what does it mean?
The SARS-Co-V2 that caused the COVID-19 pandemic did immeasurable harm to the world's population, socially, economically, psychologically. The pandemic continued in waves for about 3 years -- each wave driven by a different variant of the virus. Covid phases and health impact The first wave in 2020 was caused by the Wuhan virus that caused serious disease with hypoxia, clotting/bleeding problems and relatively moderate mortality. In India it started in March-April, peaked in September and abated by January 2021. The second wave in 2021 was caused by the Delta variant that spread far more rapidly, producing an even more serious disease. It started in February, peaked in April and retuned to baseline by June. During those months it outran the health services and caused the greatest loss of life. Memories of our experience, falling ill or watching family members or friends getting admitted in Intensive Care Units in hospitals, our elders dying in isolation, the agonising choice to take or not to take vaccine and which vaccine, lockdowns and school closures etc are still in our minds if not in the conscious level, certainly in the subconscious. Those nightmare memories are being brought forth in recent days, with the news of a resurgence of COVID-19. Electronic media keep reporting the resurgence on a daily basis, as if another wave is imminent. Truth is, no wave can occur, as we analyse the past. The third wave was caused by the Omicron variant. It started in January 2022, peaked in February and abated in March. The pandemic ended in mid-2022, and thereafter the SARS-CoV-2, exclusively the Omicron variant, has remained everywhere in the world as 'endemic' meaning thereby: continuing and constant transmission in very small numbers. We have one more disease-causing virus in circulation than pre-pandemic. Most of us have forgotten the mildness of the third wave disease. The current resurgence is caused by the Omicron sub-variants -- and the anxiety during the first two waves is no longer necessary. Variants and disease patterns Incessant mutations are a feature of SARS-CoV-2. Most resultant variants are of no consequence but of curiosity for the molecular virologists. Some variants, as indicated by the missing alphabets (Greek) were of public health interest but not of concern. Three variants of Wuhan original – Beta, Delta and Omicron were of concern. The variants of concern had higher transmissibility and the ability to evade immunity than their predecessors that lost out in competition. Thus, Delta eliminated previous variants, and Omicron eliminated the Delta variant. Infectiousness or transmissibility, can be measured. The average number of individuals infected by one infected person is denoted as the 'reproduction number' R. The higher the R, the more infectious the variant, and the faster and greater its spread. The original Wuhan variant had R of ~ 2, Delta had R of ~ 4, Omicron variant had R of ~ 8. The JN1 sub-variant of Omicron is said to have R of ~12 . The current NB.1.8.1 and XFG sub-variants must have even higher R value. Between Delta and Omicron, there was a drastic change in disease pattern. Delta caused the classic COVID-19 in its worst form. The Omicron is much more mutated than the previous variants – think of it more as 'deviant' than variant, for two reasons: one, the unusually large number of mutations on the spike protein gene and second, its disease is just like a sore throat or upper respiratory tract disease. The Omicron disease spares the lungs. It does not cause hypoxia, or bleeding/clotting disorders. It does not cause loss of smell – which is due to virus invasion of the smell apparatus, olfactory bulb. The biologic reason for the deviant behaviour is that Omicron's cell entry process is distinctly different from all other variants. Omicron infection does not cause fusion between adjacent cells – in technical terms syncytium formation. Despite all these advantages, the virus is the same species and all the above are in relative terms. Even immunity evasion is only partial – any immunity from previous variants certainly makes the subsequent infection less severe. However, those with severe co-morbidities or old age with immune senescence or immunosuppression due to any disease or disease treatment can develop severe complications affecting several body organs and may require hospitalisation and even intensive care. For them, mortality can be high. But counting their deaths does not reflect the reality of virtually no mortality in healthy population. Omicron also undergoes restless mutations, all denoted by English alphabets and numerals – they are mistakenly called variants by many, while they are all sub-variants. The currently highly prevalent subvariants including NB 1.8.1 and XFG (which is a recombinant of two earlier subvariants) are all derived from Omicron JN.1 sub-variant, and all the clinical features described for Omicron infection above are valid for all of them. Drop in testing and the false sense of security By August 2024 many countries stopped testing routinely for SARS-CoV-2 infection. That gave the false impression that the virus had stopped circulating. What happened recently, was that the countries that had continued testing reported the increasing trend of virus circulation, following which we also began testing – the more we tested, the more we found. New-born infants, about 70,000 per day in India, adding up as annual birth cohorts constitute the immunity-naïve population pool for driving the continued virus circulation. But we know next to nothing about the frequency of infections in them. Re-infection despite immunity is the norm for SARS-CoV-2. Omicron and its sub-variants became progressively more infective and had greater potential for spread. The recent number of COVID-19, reported as nearly 7,000, reflects the greater volume of testing, not the true magnitude of infection or disease in the population. The Ministry of Health is monitoring the situation and has advised testing only for patients with influenza like illness (ILI) and patients admitted with severe acute respiratory illness (SARI). Because testing is selective, the reported numbers reflect more of those with significant symptoms than the true numbers of those with mild disease. Immune escape It is of note that successive variants of the virus have clearly demonstrated the 'immune escape' phenomenon. This immune escape is partly because immunity from previous infection and from previous vaccination wanes with time. Greater infectiousness is also due to the property of 'immune evasion' by the more successful variants and sub-variants. During the 2022 Omicron wave, most new infections were in those who had immunity from past infections or immunisation or both. What is the likely outcome of this upsurge in cases? The vast majority of those infected will have mild illness like a sore throat, dry cough (since lungs are not involved), fever, headache, etc. Some get mild diarrhoea too. By virtue of previous infection and or immunisation even the elderly and immunocompromised individuals also will mostly have a mild illness. A few individuals will develop pneumonia and will need hospital admission and out of these a small number will succumb. Management of these individuals should be along established lines with supportive treatment and steroids. Antiviral drugs are unlikely to be of much help. As in all endemic viral infections, every upsurge will also peak and then decline after which the community will fall back into the steady state of endemic prevalence. What was surprising was the upsurge during high summer and very hot days. Most other respiratory viruses are more active during cooler times and rainy season. The elderly and the immunocompromised individuals are well-advised to wear masks when they have to be in crowded places and during travel by bus, train or aeroplane. This precaution is necessary even at home if another family member has upper respiratory symptoms. (Dr. M.S. Seshadri, is a retired professor of the department of endocrinology, diabetes and metabolism, Christian Medical College, Vellore. Email: Dr. T. Jacob John, is a retired professor of clinical virology, Christian Medical College, Vellore. Email: tjacobjohn@
